Fluzone Trivalent Northern Hemisphere Injection, Suspension
Product Images NDC 83703-083

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Fluzone Trivalent Northern Hemisphere (NDC 83703-083). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bamboo Us Bidco Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (0.5 mL Syringe Label)

This is a description of an influenza vaccine called Fluzone® for the 2025-2026 season. It is a preservative-free vaccine intended for intramuscular use, coming in a 0.5 mL single-dose presentation. The manufacturer is Sanofi Pasteur Inc. The specific lot number and other details are not available for reference.*

FDA Label Image

Principal Display Panel (0.5 mL Syringe Package)

This is information about the Fluzone influenza vaccine for the 2025-2026 season. It is intended for intramuscular use in individuals aged 6 months and older. The vaccine is prepared from influenza viruses grown in chicken eggs and inactivated with formaldehyde. It contains a nonionic surfactant and is standardized to contain 45 micrograms of hemagglutinin per 0.5 mL dose. The vaccine includes strains such as H1N1, H3N2, and B/Austria lineage. It does not contain preservatives or natural rubber latex. The vaccine is stored between 2 to 6°C. It is provided in single-dose prefilled syringes for easy administration.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.